You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
BIX NHE1 inhibitor
Biological Activity for BIX NHE1 inhibitor
BIX NHE1 inhibitor is a potent and selective NHE1 inhibitor (IC50 = 31 nM). Selective for NHE1 over NHE2 and NHE3. Prevents ischemic damage in an ischemia reperfusion injury isolated rat heart model ex vivo. Prevents phenylephrine-induced cardiomyocyte hypertrophy in vitro, and attenuates cardiac hypertrophy and left ventricular dysfunction postinfarction in rats. Orally bioavailable.
Technical Data for BIX NHE1 inhibitor
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for BIX NHE1 inhibitor
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for BIX NHE1 inhibitor
The following data is based on the product molecular weight 392.8. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||5.09 mL||25.46 mL||50.92 mL|
|2.5 mM||1.02 mL||5.09 mL||10.18 mL|
|5 mM||0.51 mL||2.55 mL||5.09 mL|
|25 mM||0.1 mL||0.51 mL||1.02 mL|
Product Datasheets for BIX NHE1 inhibitor
References for BIX NHE1 inhibitor
References are publications that support the biological activity of the product.
Kilić et al (2014) Early and transient sodium-hydrogen exchanger isoform 1 inhibition attenuates subsequent cardiac hypertrophy and heart failure following coronary artery ligation. J.Pharmacol.Exp.Ther. 351 492 PMID: 25216745
Huber et al (2012) Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat. J.Med.Chem. 55 7114 PMID: 22803959
If you know of a relevant reference for BIX NHE1 inhibitor, please let us know.
View Related Products by Product Action
Keywords: BIX NHE1 inhibitor, BIX NHE1 inhibitor supplier, BIXNHE1, inhibitor, sodium, hydrogen, exchanger, isoform1, inhibitors, inhibits, potent, selective, hypertrophy, ischemia, Na+/H+, Exchanger, 5512, Tocris Bioscience
1 Citation for BIX NHE1 inhibitor
Citations are publications that use Tocris products. Selected citations for BIX NHE1 inhibitor include:
Valerie M et al (2021) Adhesion-mediated mechanosignaling forces mitohormesis. Cell Metab 33 1322-1341.e13 PMID: 34019840
Do you know of a great paper that uses BIX NHE1 inhibitor from Tocris? Please let us know.
Reviews for BIX NHE1 inhibitor
There are currently no reviews for this product. Be the first to review BIX NHE1 inhibitor and earn rewards!
Have you used BIX NHE1 inhibitor?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cancer Metabolism Research Product GuideNew
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
- Tricarboxylic Acid Cycle
- 1C Metabolism and Nucleic Acid Synthesis
- Drivers of Metabolic Reprogramming
- pH and Redox Balance
Cancer Metabolism Poster
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.